DIECI, Maria Vittoria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.056
EU - Europa 1.952
AS - Asia 1.918
SA - Sud America 265
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 8.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.008
CN - Cina 628
SG - Singapore 527
GB - Regno Unito 436
IT - Italia 369
HK - Hong Kong 343
IE - Irlanda 343
BR - Brasile 220
SE - Svezia 218
DE - Germania 195
VN - Vietnam 115
RU - Federazione Russa 92
UA - Ucraina 71
FI - Finlandia 67
KR - Corea 57
IN - India 54
ID - Indonesia 49
TR - Turchia 44
FR - Francia 36
CA - Canada 34
BG - Bulgaria 31
NL - Olanda 18
ZA - Sudafrica 18
PL - Polonia 14
ES - Italia 12
IQ - Iraq 12
TW - Taiwan 12
AR - Argentina 10
BD - Bangladesh 9
CZ - Repubblica Ceca 9
JP - Giappone 9
LT - Lituania 9
MX - Messico 9
PK - Pakistan 9
CO - Colombia 8
EC - Ecuador 8
EG - Egitto 8
IR - Iran 8
AT - Austria 7
PY - Paraguay 6
VE - Venezuela 6
AU - Australia 5
BE - Belgio 5
DK - Danimarca 4
IL - Israele 4
MY - Malesia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DZ - Algeria 3
EU - Europa 3
GR - Grecia 3
JO - Giordania 3
KE - Kenya 3
PH - Filippine 3
RO - Romania 3
SA - Arabia Saudita 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BH - Bahrain 2
CH - Svizzera 2
CL - Cile 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LY - Libia 2
MM - Myanmar 2
NP - Nepal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
TJ - Tagikistan 1
VC - Saint Vincent e Grenadine 1
Totale 8.243
Salva come PNG Salva come JPEG
Città #
Santa Clara 483
Ashburn 395
Fairfield 391
Singapore 366
Dublin 343
Hong Kong 340
Woodbridge 234
Southend 229
Chandler 219
Hefei 207
Houston 176
Seattle 173
Ann Arbor 135
Cambridge 134
Dearborn 132
Wilmington 127
Jacksonville 115
Nyköping 113
London 109
Beijing 103
Los Angeles 92
Chicago 81
The Dalles 59
New York 51
Dallas 47
Modena 47
Seoul 47
Munich 45
Jakarta 44
San Diego 42
Moscow 40
Shanghai 39
Ho Chi Minh City 38
Princeton 34
Helsinki 31
Sofia 31
Hanoi 29
Milan 27
Eugene 25
São Paulo 25
Izmir 22
Tampa 21
Elk Grove Village 20
Buffalo 19
Bologna 18
Falls Church 18
Salt Lake City 18
Rome 17
Des Moines 15
Dong Ket 15
Guangzhou 15
Norwalk 15
Redwood City 15
Turin 15
Columbus 14
Kent 14
Council Bluffs 13
Naples 13
Nuremberg 13
Turku 13
Boston 12
Bremen 12
Ottawa 12
Redondo Beach 12
Phoenix 11
Frankfurt am Main 10
Fremont 10
Mumbai 10
Kunming 9
Padova 9
Warsaw 9
Amsterdam 8
Changsha 8
Denver 8
Johannesburg 8
Lancaster 8
Nanjing 8
Orem 8
Sterling 8
Taipei 8
Boardman 7
Brooklyn 7
Catania 7
Curitiba 7
Montreal 7
Wuhan 7
Florence 6
Gelsenkirchen 6
Lappeenranta 6
Parma 6
Rio de Janeiro 6
Toronto 6
Augusta 5
Belo Horizonte 5
Brno 5
Genoa 5
Hyderabad 5
Kilburn 5
Poplar 5
Ankara 4
Totale 6.026
Salva come PNG Salva come JPEG
Nome #
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 391
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 367
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 350
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 304
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 294
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 273
Immune characterization of breast cancer metastases: prognostic implications. 263
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 254
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 253
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 250
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 235
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 233
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 229
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 227
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 226
Timing for starting second-line therapy in recurrent ovarian cancer 224
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 210
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 204
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 195
Tumori ginecologici 192
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 170
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 169
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 168
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 168
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 162
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 153
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 153
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 151
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 148
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 146
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 142
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 133
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 120
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 119
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 118
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 112
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 108
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 104
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 95
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 72
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 68
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 63
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 59
Totale 8.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.162
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.162
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021644 0 0 0 0 0 109 97 104 66 120 101 47
2021/2022630 29 73 77 19 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/20251.888 54 27 30 139 360 313 138 103 182 107 188 247
2025/20261.856 271 142 305 425 630 83 0 0 0 0 0 0
Totale 8.325